Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa for chemotherapy-induced anemia
NCT00266617Phase 2Completed
- Sponsor
- Johnson & Johnson
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 2, randomised, double-blind trial in anemia comparing Epoetin alfa with Placebo (2 arms). Primary endpoints: Number of transfusions at 12 weeks, Change in hemoglobin level at 12 weeks and 2 more. Status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00266617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266617.